; bioMerieux S A BIM Product Pipeline Analysis bioMerieux S A BIM Product Pipeline Analysis
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

bioMerieux S A BIM Product Pipeline Analysis bioMerieux S A BIM Product Pipeline Analysis

VIEWS: 52 PAGES: 36

bioMerieux S.A. (BIM) - Product Pipeline Analysis Summary bioMerieux S.A. (bioMerieux) is engaged in the design, development and manufacture of diagnostic systems and reagents for physicians and biologists. It operates through two business divisions, namely, Clinical Applications and Industrial Applications. It offers diagnostic solutions such as instruments, reagents and software. The company's products are used in diagnosing infectious diseases and provide high medical value results in cancer screening and monitoring and cardiovascular emergencies. Its products also detect microorganisms in food, pharmaceutical and cosmetic products. Its operations are spread over 150 countries through 39 subsidiaries and have a broad network of distributors. The company is headquartered in Marcy l’Etoile, France. This report is a source for data, analysis and actionable intelligence on the bioMerieux S.A. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date. Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Scope - Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments. - Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase. - Information on product milestones and pipeline

More Info
  • pg 1
									                                            bioMerieux S.A. (BIM) - Product Pipeline Analysis

     Reference Code: GDAEME643PD                                                                                                   Publication Date: MAY 2011



     Company Snapshot                                                            Company Overview
     Key Information
                                                                                 bioMerieux S.A. (bioMerieux) is engaged in the design, development and
      bioMerieux S.A., Key Facts                                                 manufacture of diagnostic systems and reagents for physicians and
                                                                                 biologists. It operates through two business divisions, namely, Clinical
      Web Address                            www.biomerieux.com
                                                                                 Applications and Industrial Applications. It offers diagnostic solutions such
      Turnover (in USD Million) 1,809.30                                         as instruments, reagents and software. The company's products are used
                                                                                 in diagnosing infectious diseases and provide high medical value results in
      Number of Employees                    6,378                               cancer screening and monitoring and cardiovascular emergencies. Its
      Industry                               Energy and Utilities                products also detect microorganisms in food, pharmaceutical and cosmetic
      Source:Primary / Secondary Research                                        products. Its operations are spread over 150 countries through 39
      GlobalData                                                                 subsidiaries and have a broad network of distributors.



     bioMerieux S.A. Pipeline Products

      bioMerieux S.A. Key Pipeline Products by Equipment Type                    bioMerieux S.A. Key Pipeline Products by Therapy Area

     Equipment Type                                             No of Products   Therapy Area                                                 No of Products
     Infectious Immunology                                                 10    Methicillin resistant Staphylococcus aureus                              2
                                                                                 infection
     Immuno Chemistry                                                       6    Bacterial infection                                                        1
     Microbiology Culture                                                   1    Bladder cancer                                                             1
     Haematology                                                            1    Bloodstream infection                                                      1
                                                                                 Breast cancer                                                              1
                                                                                 Cancer                                                                     1
                                                                                 Cardiovascular diseases                                                    1
     Source: Primary / Secondary Research
                                                                                 Source: Primary / Secondary Research
     GlobalData
                                                                                 GlobalData


     bioMerieux S.A. Key Pipeline Products by Equipment Type




      Source: Primary / Secondary Research
      GlobalData



      bioMerieux S.A. Key Pipeline Products by Development Stage                 bioMerieux S.A. Key Pipeline Products by Trial Phase

     Developmental Stage                                        No of Products   Trial Phase                                                  No of Products
     Clinicals                                                              9    Phase IV                                                 -
     Pre-Clinicals                                                               Phase III                                                -
                                                                    -
     Early development                                                      8    Phase II                                                 -
     In Approval Process                                                    1    Phase I                                                  -
     Source: Primary / Secondary Research                                        Source: Primary / Secondary Research
     GlobalData                                                                  GlobalData
     Note : (-) indicates 'Not Available'                                        Note : (-) indicates 'Not Available'




bioMerieux S.A. (BIM) - Product Pipeline Analysis                                                                                       Reference Code: GDAEME643PD

Source : www.globalcompanyintelligence.com                                                                                                                       Page 1
     Table of Contents
     Table of Contents................................................................................................................................................................................................................................................................... 2
     List of Tables .......................................................................................................................................................................................................................................................................... 4
     List of Figures......................................................................................................................................................................................................................................................................... 5
     bioMerieux S.A. - Business Description ................................................................................................................................................................................................................................. 6
     Key Facts ............................................................................................................................................................................................................................................................................... 6
     bioMerieux S.A. - Major Products and Services..................................................................................................................................................................................................................... 7
           bioMerieux S.A. Pipeline Products by Equipment Type .................................................................................................................................................................................................. 9
           bioMerieux S.A. Pipeline Products by Development Stage ........................................................................................................................................................................................... 11
           bioMerieux S.A. Pipeline Products by Therapy Area..................................................................................................................................................................................................... 13
           bioMerieux S.A. Pipeline Products by Milestone Summary........................................................................................................................................................................................... 15
           Biomerieux's VRE Assay ............................................................................................................................................................................................................................................... 17
                 Product Status......................................................................................................................................................................................................................................................... 17
                 Product Description ................................................................................................................................................................................................................................................. 17
           bioNexia-BTA Tumor Marker ......................................................................................................................................................................................................................................... 17
                 Product Status......................................................................................................................................................................................................................................................... 17
                 Product Description ................................................................................................................................................................................................................................................. 17
           bioNexia-Chlamydia Point-Of-Care Assay..................................................................................................................................................................................................................... 17
                 Product Status......................................................................................................................................................................................................................................................... 17
                 Product Description ................................................................................................................................................................................................................................................. 18
           bioNexia-CRP Point-Of-Care Assay .............................................................................................................................................................................................................................. 18
                 Product Status......................................................................................................................................................................................................................................................... 18
                 Product Description ................................................................................................................................................................................................................................................. 18
           bioNexia-FOB Tumor Marker......................................................................................................................................................................................................................................... 18
                 Product Status......................................................................................................................................................................................................................................................... 18
                 Product Description ................................................................................................................................................................................................................................................. 18
           bioNexia-Respiratory Panel Point-Of-Care Assay ......................................................................................................................................................................................................... 19
                 Product Status......................................................................................................................................................................................................................................................... 19
                 Product Description ................................................................................................................................................................................................................................................. 19
           bioNexia-Troponin Assay............................................................................................................................................................................................................................................... 19
                 Product Status......................................................................................................................................................................................................................................................... 19
                 Product Description ................................................................................................................................................................................................................................................. 19
           Breast Cancer Theranostic Assay ................................................................................................................................................................................................................................. 19
                 Product Status......................................................................................................................................................................................................................................................... 19
                 Product Description ................................................................................................................................................................................................................................................. 20
                 Product Milestone ................................................................................................................................................................................................................................................... 20
           C. Difficile Assay............................................................................................................................................................................................................................................................ 20
                 Product Status......................................................................................................................................................................................................................................................... 20
                 Product Description ................................................................................................................................................................................................................................................. 20
           KPC Assay..................................................................................................................................................................................................................................................................... 21
                 Product Status......................................................................................................................................................................................................................................................... 21
                 Product Description ................................................................................................................................................................................................................................................. 21
           MRSA Assay.................................................................................................................................................................................................................................................................. 21
                 Product Status......................................................................................................................................................................................................................................................... 21
                 Product Description ................................................................................................................................................................................................................................................. 21
           NDM-1 Assay................................................................................................................................................................................................................................................................. 21
                 Product Status......................................................................................................................................................................................................................................................... 21
                 Product Description ................................................................................................................................................................................................................................................. 22
           New Blood Culture System............................................................................................................................................................................................................................................ 22
                 Product Status......................................................................................................................................................................................................................................................... 22
                 Product Description ................................................................................................................................................................................................................................................. 22
           NucliSENS EasyQ-MRSA Assay................................................................................................................................................................................................................................... 22
                 Product Status......................................................................................................................................................................................................................................................... 22
                 Product Description ................................................................................................................................................................................................................................................. 22
           Point Of Care Testing Device ........................................................................................................................................................................................................................................ 23
                 Product Status......................................................................................................................................................................................................................................................... 23
                 Product Description ................................................................................................................................................................................................................................................. 23
           Sepsis Assay ................................................................................................................................................................................................................................................................. 23
                 Product Status......................................................................................................................................................................................................................................................... 23
         
								
To top